07:00 – 11:00    YOUNG INVESTIGATOR'S SESSION
Chairs: Silvia Novello, Italy; Heather Wakelee, USA

The Future of Lung Cancer: Better Detection, Better Targeting
Better Detection
1) Finding the Lung Cancer Stem Cell - John Minna, USA
2) Improvements in Early Detection - James Jett, USA
3) New Imaging Tools for Diagnosis and Therapy Monitoring in Lung Cancer - Homer Macapinlac, USA
4) Non-invasive Mediastinal Staging - Stefano Gasparini, Italy

Better Targeting
5) Gene Expression Profiling for Diagnosis and Therapy - Anil Potti, USA
6) Pharmacogenomic based Strategies for Diagnosis and Therapy - Louis Paz-Arez, Spain
7) Biomarkers for Targeted Agents - John Heymach, USA
8) Trials Designs for Biomarker Assessment - Lucinda Billingham, UK

• Overview – David Gandara, USA
• Biomarker Development: Muddy Waters – Harvey Pass, USA
• Emerging Methodologies – Fred Hirsch, USA
• Genomic Strategies for Personalized Therapy – Joseph Nevins, USA
• Pharmacogenomic Approaches - Giorgio Scagliotti, Italy

Basic Science and Translational Research
Cancer Control and Epidemiology
Health Services Resources
NSCLC Advanced Disease
Tobacco Control

Poster Presentations (pdf) updated 13 July

• Using Biomarkers to Predict Response to EGFR Inhibitors – Mark Kris, USA
• Biology of the EGF Pathway – Yosef Yarden, Israel
• Using Biomarkers to Predict Response to EGFR Inhibitors - Mark Kris, USA
• Management of Toxicities of Anti-Angiogenic/Anti-EGFR agents – Roman Perez-Soler, USA
• State of the Art of Clinical Research with Monoclonal Antibodies – Jean-Yves Douillard, France

• Src as a Target - Dean Fennell, UK
• m-Tor Inhibitors - Lucio Crino, Italy
• HSP Inhibitors - Kenneth O’Byrne, Ireland
• HDAC Inhibitors - Lee Krug, USA
• Pro-apoptotic Agents - Rolf Stahel, Switzerland

• The Merits of Traditional Bronchoscopic Transbronchial Needle Aspiration - Stefano Gasparini, Italy
• The Advantages of Endobronchial Ultrasound Guided Needle Aspiration - Heinrich Becker, Germany
• Endoscopic Ultrasound Guided Needle Biopsy: Complementary or First Line? - Louis Irving, Australia
• Electromagnetic Navigation Guided Biopsy of Mediastinal Lymph Nodes. The Latest Technology - Felix Herth, Germany

• PPARgamma as a target for Aerodigestive Chemoprevention - Frank Ondrey, USA
• The Balance Between Cell Survival and Cell Death in Lung Cancer Chemoprevention - Shi-Yong Sun, USA
• Emerging Models for Lung Carcinogenesis - Luis Montuenga, Spain

• Tumor Hypoxia, Angiogenesis and Lung Cancer - Joan Schiller, USA
• Predictive Plasma Biomarker Profiles - Suresh Ramalingam, USA
• Therapeutic Combinations with Bevacizumab - Antoinette Wozniak, USA
• Role of Anti-Angiogenic TKI’s - Heather Wakelee, USA
• Clinical Factors in Selecting Patients for Anti-Angiogenic Therapy - Alan Sandler, USA

• Histopathological Diagnosis on Frozen Examination - Lucian Chirieac, USA
• FNA Diagnosis - Getting the most out of it - Lukas Bubendorf, Switzerland
• Assessment of Cytological Samples - Maureen Zakowski, USA
• Gene Copy Number and Genetic Instability - Iver Petersen, Germany
• Assessment of Invasion Before Surgery - Alain Borczuk, USA

• Aurora Kinase Inhibitor + Radiation for NSCLC - Bo Lu, USA
• Src Kinase Inhibition and Radiation in NSCLC - David Raben, USA
• PARP Inhibition and Tumour Radio Sensitivity – Ian Stratford, UK
• Imaging with 18F-3-deoxy-3-fluoro-l-thymidine (FLT) positron emission tomography in patients with lung cancer - Michael MacManus, Australia

• Inflammatory Proteins - Eva Szabo, USA
• IGF-1R Pathway - Fadlo Khuri, USA
• Chemoprevention: EGFR Targeted Agents  - York Miller, USA
• COX/LOX Inhibition -Jenny Mao, USA

• Challenges of Tobacco Control in the US - Stanton Glantz, USA
• Tobacco Control Strategies in Europe - John Britton, UK
• Tobacco Epidemic and Tobacco Control in China - Xiuyi Zhi, China
• Tobacco Control in South America - Nise Yamaguchi, Brazil
• Smoking Cessation in Asia - Jin Soo Lee, South Korea

• Mucositis and Lung Cancer - Dorothy Keefe, Australia
• Emesis - Steven Grunberg, USA
• Fatigue in SNCLC: Etiology, Impact and Treat Options - John Eckhardt, USA
• Cutaneous Toxicities - Mario Lacouture, USA

• Neoadjuvant Chemotherapy - Steven Keller, USA
• Adjuvant Chemotherapy - Nasser Hanna, USA
• Pharmacogenomic Approaches - Rafael Rosell, Spain
• Predictive Markers - David Harpole, USA

• Current Screening Trial Results - James Jett, USA
• Evaluation of Indeterminate Pulmonary Nodule/GGO - Yasuo Nakajima, Japan
• Ancillary Findings on Screening Studies - Stephen Swensen, USA

• History of Anti-Angiogenesis-based therapies in the treatment of NSCLC – Philip Bonomi, USA
• State of the Art of Clinical Research with Monoclonal Antibodies - David Johnson, USA
• State of the Art of Clinical Research with Small VEGF-TKI Molecules - Thierry Jahan, USA
• Management of Toxicities of Anti-Angiogenic/Anti-EGFR agents - John Heymach, USA

• Multiple Tyrosine Kinase Inhibitors : What is the Rationale and the Clinical Evidence? - Chandra P. Belani, USA
• IGF1R Pathway : Rationale and Inhibitors – Ross Camidge, USA
• ASA404, A Novel Tumor Vascular Disrupting Agent (VDA): Rationale for Advanced Non-Small Cell Lung Cancer Therapy – Primo Lara, USA
• Emerging EGFR biomarkers - Thomas Lynch, USA
• DNA Repair Mechanisms to Tailor Therapy in NSCLC- Jean Charles Soria, France

• Clinical Results - Nasser Altorki, USA
• Standardizing Acquisition Parameters and Imaging Quality -David Yankelevitz, USA
• Development of Image Processing Tools for Drug Response Evaluation - Rick Avila, USA
• NeoAdjuvant Trial with RAD001 - Fadlo Khuri, USA
• Challenges of Neoadjuvant Window of Opportunity Trials - Purvish Parikh, India

• Neoadjuvant Chemotherpay Past and Present US Trials – Martin Edelman, USA
• Neoadjuvant Chemotherapy Past and Present European Trials - Bernard Milleron, France
• S9900 Trial Update, Mature Analysis - Katherine Pisters, USA
• Surgical Issues with Neoadjuvant Trials- Is the Surgical Risk Increased? - Kemp Kernstine, USA

• Early Detection of Lung Cancer using an Electronic Nose - Annette McWilliams, Canada
• Optical Coherence Tomography - Stephen Lam, Canada
• Autofluorescence-Reflectance Imaging - Norihiko Ikeda, Japan
• Narrow band imaging is a new investigatory tool to visualize angiogenesis in squamous cell carcinoma of the lung - Kiyoshi Shibuya, Japan
• Confocal Micro-Endosocopy - Luc Thiberville, France

• ERCC1 and RRM1 – Predictive vs. Prognostic Roles - George Simon, USA
• BRCA1 Gene and Sensitivity to Lung Cancer Chemotherapy - Rafael Rosell, Spain
• Thymidylate Synthase as a Marker of Sensitivity to Anti-Folates - Giorgio Scagliotti, Italy
• KRAS as a Marker of Chemoresistance - Ming Tsao, Canada
• Genomic Strategies to Guide Standard Chemotherapy - Joseph Nevins, USA

• Techniques of VATS Resections for Lobectomy, Segmentectomies, and Lymph Node Dissections and Their Results in 2009: Who are the Candidates, When Do You Not Do This? - Thomas D’Amico, USA
• Evidence for the Use of Sublobar vs Lobar Resections for the Medically Operable Lung Cancer Patient: A Complete Review of the Literature with Most Recent Results - Shun-ichi Watanabe, Japan
• Intraoperative Techniques for the Prevention of Positive Margins - Sue Yom, USA
• Management of the Patient with Multiple Synchronous/Metachronous Pulmonary Lesions: Lobectomies, Segmentectomies, Wedge Resections, Simultaneous, Staged, How much Staging? -  Kenji Suzuki, Japan

• Smoking Cessation Strategies in Women - Carolyn Dresler, USA
• Genetic Susceptibility to Lung Cancer in Women - Julie Brahmer, USA
• Estrogen and Progesteron Receptors in Lung Cancer - Jill Siegfried, USA
• Sex as a Prognostic and Predictive Factor - Silvia Novello, Italy
• Clinical and Epidemiologic Features of Lung Cancer in Asian Females - Sumitra Thongprasert, Thailand

• For STR in Inoperable Tumor - Robert Timmermann, USA
• Against SRT in Inoperable Tumors – David Ball, Australia
• For STR in Operable Tumors – Suresh Senan, Netherlands
• Against SRT in Operable Tumors – Paul van Schil, Belgium

• Conventional Imaging (CT, MR) - Ann Leung, USA
• CT/PET Staging - Jeremy Erasmus, USA
• Endoscopic Ultrasound (EBUS-EUS) for staging and follow up of lung cancer -  Kazuhiro Yasufuku, Canada
• Imaging Response and Surveillance (PET, CT) - Homer Macapinlac, USA
• Molecular Diagnostics and New Imaging Probes - Ramsey Badawi, USA

• The Asbestos Threat: A World-Wide Overview of the Epidemiology of Asbestos Exposure - Ken Takahashi, Japan
• Non-Asbestos Related Mesothelioma: The Role of SV40 - Michele Carbone, USA
• Current MM Lab Studies and their Possible Translation - Robert Kratzke, USA
• Gene Therapy/Immunotherapy and Mesothelioma: Where Are We - Steven Albelda, USA

• Phase I and II Strategies for Choosing a Good Dose with Targeted Agents - John Crowley, USA
• Phase I Designs for Identifying a Blologically Optimal Dose - Sumithra Mandrekar, USA
• Dose Escalation Trials Based on a Molecularly Targeted Endpoint - Sally Hunsberger, USA
• A Clinician's Perspective - Derick Lau, USA

• Surgery – Masahiro Tsuboi, Japan
• Radiotherapy – Hak Choy, USA
• Chemotherapy – Everett Vokes, USA
• Targeted Therapy for Non-Small Cell Lung Cancer – Frances Shepherd, Canada

Endoscopy and Intervention Bronchoscopy
Imaging
Mesothelioma, Thymoma and Others
Non-Small-Cell Lung Cancer - Early Disease
Novel Therapeutics and Modalities
Pulmonary Medicine
Small Cell Lung Cancer
Surgery

Poster Presentations (pdf) updated 16 July

• Front Line Studies Using Clinical Parameters for EGFR-TKIs  - Tony Mok, Hong Kong
• Epidermal growth factor receptor assessment in prospective studies – Rafal Dziadziusko, Poland
• How to Design a Meta-Analysis in Biomarkers - Lucinda Billingham, UK
• Prospective Studies with Proteomics – Vanesa Gregorc, Italy
• Histology As A Selection Factor for Treatment – Shirish Gadgeel, USA

• Surgical Management of Malignant Pleural Effusions - Raja Flores, USA
• Thoracoscopy - John Beamis, USA
• PleurX Catheter Placement - Alain Tremblay, Canada
• Implanted Port Reservoir for Pleural Drainage – Ken Yoneda, USA

• DNA Methylation Markers in Lung Cancer - Sabine Zöchbauer-Müller, Austria
• Somatic Mutations in Lung Cancer - Monserrat Sanchez-Caspedes, Spain
• Molecular Changes in Invasion, Tumor Progression and Metastasis - Wilbur Franklin, USA

• Stem Cell Population in Mouse Lung Cancer - Allan Balmain, USA
• Prognostic Markers                                                             
• Wnt Pathway in Lung Cancer - Liang You, USA
• The Hedgehog signaling pathway in lung cancer: moving beyond inhibition of cell growth - Rajat Rohatgi, USA
• Notch - Noemi Reguart, Spain
• Upcoming Therapeutics: Preclinical to Clinical - Biao He, USA
• Lung Cancer Stem Cells and Their Application to Future Prevention Research - John Minna, USA

• Biomarkers: What Do We Know and How Do We Use Them? - Bruce Robinson, Australia
• What is the Standard Treatment of MPM? First and Second Line - Paul Baas, Netherlands
• The Challenges of New Drug Development for Mesothelioma - Hedy Kindler, USA

• Cost Studies in Lung Cancer-What’s the Purpose? - James Bishop, Australia
• The Use, Cost and Cost-Effectiveness of Chemotherapy in NSCLC -  Scott Ramsey, USA
• Molecular Targeted Therapy – Can We Afford It? - William Evans, Canada

• The New IASLC/ATS/ERS International Multidisciplinary Lung Adenocarcinoma Classification - William Travis, USA
• Compartment Concept for Lung Cancer Pathogenesis - Ignacio Wistuba, USA
• Expression profiling-based approaches for a better understanding of human lung cancer biology - Takashi Takahashi, Japan
• In Situ, Invasion, Extension as Prognostic Factors in adenocarcinoma - Masayuki Noguchi, Japan

• Which Tool of Measurement? - Peter Harper, UK
• Defining Clinically Relevant Changes in QOL Measurements -  David Cella, USA
• Improving Compliance in QOL Measurement With Web-Based Tools -  James Rigas, USA
• Long-term QOL Following Surgery for NSCLC -Pierre Theodore, USA

• Current status of Stereotactic Body Radiation Therapy (SBRT) - Yasushi Nagata, Japan
• Radiofrequency Ablation - Hiran Fernando, USA
• Stage Specific Therapy for NSCLC:Choosing the right operation - Mark Krasna, USA

• Chemoprevention in the 21st Century - Edward Kim, USA
• High Throughput Screening and the Selection of Natural Compounds for Prevention - Haian Fu, USA
• Transgenic Mouse Models as Tools for Lung Cancer Chemoprevention - Ethan Dmitrovsky, USA

• National Lung Cancer Partnership : The US Approach - Joan Schiller, USA
• Lung Cancer Advocacy - The European Appraoch - Jesme Fox, UK
• Lung Cancer Alliance: How to Succeed in Increasing the Awareness about Lung Cancer - Laurie Fenton-Ambrose, USA
• Bonnie J. Addario Lung Cancer Foundation: Bridging to the Future - Bonnie Addario,USA
• The Role of Media in Increasing the Awareness About Lung Cancer –  John Seng, USA

• What Should be the Standard of Care Outside Clinical Trials? - Walter Curran, USA
• Radiation Volume Considerations in Combined Modality Therapy - Laurie Gaspar, USA
• When is Concurrent Chemo-Radiation Not the Treatment of Choice in Inoperable Stage III Disease? - Fergus Macbeth, UK
• Integration of Novel Targeted Therapy to Combined Chemoradiation – What Agent and What Settings? - Quynh-Thu Le, USA

• Mechanisms of Drug Resistance with Cytotoxics  – Miquel Taron, Spain
• Maintenance With Cytotoxics  – Karen Kelly, USA
• Maintenance with EGFR Agent - Jacek Jassem, Poland
• Maintenance with VEGF Agent - Roy Herbst, USA
• Role of Radiotherapy in the Management of Metastatic Disease - Dirk De Ruysscher, Netherlands

• Epidemiology of SCLC - Ramaswamy Govindan, USA
• Small Cell Lung Cancer : Current Standards – Kaoru Kubota, Japan
• Targeted Therapies : The Available Evidence  - Bruce Johnson, USA
• Novel systemic therapies for small cell lung cancer  - Charles Rudin, USA

• Differential Diagnoses - Kazuma Kishi, Japan
• PET For Diagnosis and Staging - Johan Vansteenkiste, Belgium
• Preoperative Evaluation of Pulmonary Function - Kwun Fong, Australia
• Pulmonary Complications in the Treatment of Lung Cancer - Julien Mazieres, France
• Interventional Bronchoscopy - Pyng Lee, Singapore

• Lung Carcinogenesis Detected by Exhaled Breath Approaches - Simon Spivack, USA
• Novel Genomic Applications in Lung Cancer: What Are The Latest SNPs and CHIPs? - Mark Geraci, USA
• Development of Gene Methylation as a Biomarker for Lung Cancer Detection - Steven Belinsky, USA
• Proteomics - Pierre Massion, USA
• Plasma DNA as a Biomarker for Lung Cancer Detection and Prognosis - Gabriella Sozzi, Itlay

• EGFR AND KRAS mutations in lung adenocarcinomas: Two contrasting and mutually exclusive mechanisms for pathogenesis -Tetsuya Mitsudomi, Japan
• Resistance Factors to EGFR TKIs - William Pao, USA
• Second-Generation EGFR Inhibitors and Combinations - Ulrich Gatzemeier, Germany
• Prediction of Benefit from EGFR TKIs by Proteomic Analysis of Pre-treatment Serum - David Carbone, USA
• EGFR Immunohistochemistry: Prediction of Benefit from Gefitinib - Federico Cappuzzo, Italy

• New Gene Signatures - David Jablons, USA
• Cyclooxzgenase-2 in Lung Cancer – Karen Reckamp, USA
• Advances in Mouse Models of Lung Cancer - Ilona Linnoila, USA
• Isolation and expansion of the tumorigenic lung cancer stem cell population - Ruggero De Maria, Italy

• What is the Definition of “Resectable N2 Disease”?- Surgeon’s View - Walter Weder, Switzerland
• What is the Definition of “Resectable N2 disease”?-Medical Oncologist’s View - Wilfred Eberhardt, Germany
• Role of Pneumonectomy in the Management of Resectable Non-Small Cell Lung - Rodney Landreneau, USA
• Surgical Complications for Pre-Operative Therapy -Dominique Grunenwald, France

• Vascular Sleeve Resections -Shaf Kehsavjee, Canada
• Involvement of the T-spine, including Pancoast Tumor - Garret Walsh, USA
• Guidelines for Intraoperative Lymph Node Staging - Bernward Passlick, Germany
• Extent of surgery for synchronous/metachronous pulmonary lesions: Prognostic Implications and Importance of CT Appearance in the Decision Making - Hisao Asamura, Japan

• Oral Iloprost for the Chemoprevention of Lung Cancer - Robert Keith, USA
• Targeting mTOR for lung cancer prevention - Philip Dennis, USA
• Zileuton - Omer Kucuk, USA
• New Avenues for Chemoprevention - Steven Dubinett, USA

• Expectation of Potential Outcomes with "Best Practice" Screening - Claudia Henschke, USA
• Outcome Measures in the National Lung Screening Trial - Ugo Pastorino, Italy
• Defining the "High Risk Cohort " for Lung Cancer Screening - Rob J. Van Klaveren, Netherlands

• Pro: Francoise Mornex, France
• Con:  Noah Choi, USA

• Percutaneous Biopsies - Elizabeth Moore, USA
• Radiofrequency Ablation - Robert Suh, USA
• Stenting and Embolization - Robert Kerlan, USA

• Surgery in Mesothelioma: YES - David Sugarbaker, USA
• Surgery in Mesothelioma: NO - Nick Pavlakis, Australia

• State of the IASLC - Nagahiro Saijo, Japan
• Mutations and copy number gains of KRAS gene correlate with biological activity of ras and clinical outcome in lung adenocarcinomas - Junichi Soh, University of Texas Southwestern Medical Center at Dallas, USA
  Discussant: Tetsuya Mitsudomi, Japan
• Evolution of gene expression and biological pathways involved at successive steps of lung squamous carcinogenesis - Celine Mascaux, Institut Jules Bordet, ULB, Belgium
  Discussant: John Minna, USA
• A phase III randomized trial of surgery (S) alone, or preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early stage non-small cell lung cancer (NSCLC): NATCH follow-up data - Enriqueta Felip, Vall d'Hebron University Hospital, Spain
  Discussant: David Jablons, USA
• A Randomized Phase III Study of Gefitinib (IRESSATM) versus Standard Chemotherapy (Gemcitabine plus Cisplatin) as a First-line Treatment for Never-smokers with Advanced or Metastatic Adenocarcinoma of the Lung - Jin Soo Lee, National Cancer Center Korea, Korea
  Discussant: Frances Shepherd, Canada

Combined Modality Therapy
Early Detection and Chemoprevention
Oncology Nursing
Pathology
Patient Advocacy
Prognostic and Predictive Markers
Radiotherapy
Supportive and Palliative Care

Poster Presentations (pdf) updated 16 July

• Medical and Radiation Oncology - Nevin Murray, Canada
• Surgery - David Cooke, USA
• Pathology - Kirk Jones, USA
• Mesothelioma - Hedy Kindler, USA

• Overview – Peter Goldstraw, UK
• Pathologic Implications - Elisabeth Brambilla, France
• Imaging Implications – Edward Patz, USA
• Taking the New Staging System into the Clinic – Valerie Rusch, USA

Combined Modality Therapy
Early Detection and Chemoprevention
Oncology Nursing
Pathology
Patient Advocacy
Prognostic and Predictive Markers
Radiotherapy
Supportive and Palliative Care

Poster Presentations (pdf) updated 16 July

• NSCLC Advanced Disease & Imaging - Michael Cullen, UK
• Basic Science & Translational Research - Sanjay Popat, UK
• Surgery - Masahiro Tsuboi, Japan
• Combined Modality Therapy - Francoise Mornex, France
  

• Systemic Chemotherapy : The Current Evidence  - Howard “Jack” West, USA
• Is There Still a Role for Adjuvant Radiotherapy? - Rodrigo Arriagada, France
• Vaccine as Adjuvant Treatment for Non-Small Cell Lung Cancer (NSCLC) – Charles  Butts, Canada
• Antifolate in the Adjuvant Setting - Yukito Ichinose, Japan

• Optimizing Supportive Care in Lung Cancer: Recent Advances in Antiemetics - Paul Hesketh, USA
• Evaluations of Symptoms and Quality of Live in Patients with Lung Cancer - Richard Gralla, USA
• Anemia - Corey Langer, USA
• Bone Metastases - Carlo Barrios, Brazil
• Dyspnea: Evaluation and Management Strategies - Lorriana Leard, USA

• Virtual Bronchoscopic Navigation - Fumihiro Asano, Japan
• Electromagnetic Navigation - Doug Arenberg, USA
• Endobronchial Ultrasonography for Peripheral Lung Lesions - Noriaki Kurimoto, Japan
• EBUS-TBNA: A safe and accurate modality for mediastinal staging - Takehiko Fujisawa, Japan

• Oncogene Discovery in Lung Adenocarcinoma - Matthew Meyerson, USA
• Proteomics - David Carbone, USA
• MicroRNA Signatures for Outcome Prediction of Lung Cancer Patients - Pan-Chyr Yang, Taiwan
• Genomic Signatures -  Anil Potti, USA
• Gene Expression in the Airways - Avrum Spira, USA

• Signal Transduction Overview - Paul Bunn Jr., USA
• C-Met Inhibitors - Ravi Salgia, USA
• Src Inhibitors - Oliver Gautschi, Switzerland
• MEK Inhibitors - Alex Adjei, USA
• IGF-1R Inhibitors - Luis Paz-Ares, Spain

• Lung Cancer Staging: Latest Revision - Frank Detterbeck, USA
• How New Staging Affects Surgical Perspectives - Ramon Rami-Porta, Spain
• Pleural Invasion - Victor Roggli, USA
• Multiple Tumor Nodules: characteristics of lung cancers with multiple nodules from BAC to ALK fusion gene carcinoma - Yuichi Ishikawa, Japan

• Clinical Use of the Erythropoietin Stimulating Agents: Defining the Benefits - Robert Pirker, Austria
• Clinical Use of the Erythropoietin Stimulating Agents: Defining the Risks -  Paris Kosmidis, Greece
• Role of Myeloid Growth Factors in Lung Cancer - Jeffrey Crawford, USA

• Imaging of the Mediastinum after Induction Therapy - Paul De Leyn, Belgium
• EBUS with or without EUS - Mark Krasnik, Denmark
• Repeat Mediastinoscopy -  Laureano Molins, Spain

• Chemoprevention of High Risk Patient Populations - Nico Van Zandwijk, Australia
• Development of Molecular Risk Models for Lung Cancer - Margaret Spitz, USA
• Convergence Between Adjuvant and Prevention Approaches - Scott Lippman, USA
• Gene Promoter Methylation as a Biomarker to Assess Selenium Chemoprevention for Lung Cancer - Steven Belinsky, USA

• The Role of PET Imaging for Radiation Treatment Planning and Adaptive Radiation Therapy - Feng-Ming Kong, USA  
• Pitfalls of Motion Management Strategies in 4-D Radiation Therapy - William Loo, USA
• IMRT for lung cancer:Good or Bad - Ritsuko Komaki, USA  
• The Status of Particle Beam Therapy for Lung Cancer - Hirohiko Tsujii, Japan
• Beyond IGRT- A Look To The Future - Maria Werner Wasik, USA  

• Overview: Molecular Epidemiology of Lung Cancer - Christine Ambrosone, USA
• Biomarkers of Polycyclic Aromatic Hydrocarbon - DNA Damage and Cigarette Smoke Exposure - Regina Santella, USA
• Role of EGFR pathway activation in Never Smoking Patients with Lung Cancer - Philip Mack, USA
• Polymorphisms of DNA Repair Genes and Tobacco-related Carcinogenesis - David Christiani, USA

• Adaptive Designs Based on Biomarkers - Jack Lee, USA
• Phase III Trial Designs for Targeted Agents - Mary Redman, USA
• A Clinical  Researcher's Perspective - Hideo Kunitoh, Japan